

Axe maladies endocriniennes et métaboliques

Publications 2006 – 2009

Ardilouze JL

1. J. Ménard, H. Payette, N. Dubuc, **JP. Baillargeon**, P. Maheux, **JL. Ardilouze**. Quality of life in type 2 diabetes patients under intensive multitherapy. *Diabetes & Metabolism* 2007 Feb; 33(1):54-60.
2. Arguin A, Bouchard DR, Labonté M, **Carpentier AC, Ardilouze JL.**, Dionne IJ, Brochu M. Correlation between the rate of weight loss and changes in body composition in obese postmenopausal women after 5 weeks: A pilot study. *Applied Physiology, Nutrition and Metabolism*. 2008; 33(2):347-55.
3. *AM. Côté, LA Magee, **JL. Ardilouze**, P von Dadelszen. Microalbuminuria and the Hypertensive Disorders of Pregnancy. Accepté dans *Current Hypertension Reviews*. (Accepté le 10/02/09)
4. C. Roberge, **A.C. Carpentier, MF. Langlois, JP. Baillargeon, JL. Ardilouze**, P. Maheux, **N. Gallo-Payet**. Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity. *American Journal of Physiology: Endocrinology and Metabolism* 2007; 293(6):E1465-78
5. CN. Kamga-Ngandé, **AC. Carpentier**, F. Nadeau-Marcotte, **JL. Ardilouze, JP. Baillargeon**, D. Bellabarba, G. Houde, **MF. Langlois**. Effectiveness of a multidisciplinary program for management of obesity: the Unité d'Enseignement, de Traitement et de Recherche sur l'Obésité (UETRO) Database study. *Metabolic syndrome and related disorders* 2009;7(4):297-304.

Baillargeon JP

1. **Baillargeon JP**, Diamanti-Kandarakis E, Ostlund Jr RE, Apridonidze T, Luomo M J, Nestler JE. Altered D-Chiro-Inositol Metabolism in Women With Polycystic Ovary Syndrome. *Diabetes Care* 2006; 29(2): 300-305.
2. **Baillargeon JP, Carpentier AC**. Brothers of women with polycystic ovary syndrome are characterized by insulin resistance, decreased glucose tolerance and other metabolic anomalies. *Diabetologia* 2007; 50(12): 2424-2432.
3. Gagnon C, **Baillargeon JP**. Predictive value of fasting glucose for the screening of abnormal glucose tolerance in women with polycystic ovary syndrome. *CMAJ* 2007; 176(7): 933-938.
4. **Baillargeon JP**, Nestler JE, Ostlund Jr RE, Apridonidze T, Diamanti-Kandarakis E. Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism. *Hum Reprod*. 2008; 23(6):1439-46.
5. Villeneuve MC, Ostlund Jr. RE, **Baillargeon JP**. Hyperinsulinemia is Closely Related to Low Urinary Clearance of D-Chiro-Inositol in Brothers of Women with Polycystic Ovary Syndrome and Control Men. *Metabolism* 2009; 58(1):62-8.

Boissonneault G.

1. St-Amant, C., Lussier, S., Laberge, R.M., Lehoux, J. and **Boissonneault, G.** Phosphorylation status of topoisomerase I as a major determinant of resistance to Topotecan in ovarian cancer cells. *Biochemistry & Cell Biology* 84:55-66, 2006
2. Bissonnette, N., Lévesque-Sergerie, J.P. and **Boissonneault, G.** Spermatozoal transcriptome profile as marker for bull fertility and sperm motility: A potential tool to evaluate semen quality *Reproduction*, 138: 65-80, 2009
3. Leduc, F., Maquennehan, V., Bikond-Nkoma, G. and **Boissonneault, G.** DNA damage response during chromatin remodeling in elongating spermatids. *Biology of Reproduction*, 78: 324-332, 2008
4. Leduc, F. Bikond-Nkoma, G. and **Boissonneault, G.** Spermiogenesis and DNA repair: A possible etiology of human infertility and genetic disorders. *Archives of Andrology: Journal of Reproductive Systems*, 54:1-8, 2008
5. Leduc F, Maquennehan V, Nkoma GB, **Boissonneault G.** DNA damage response during chromatin remodeling in elongating spermatids of mice. *Biol Reprod.* 2008; 78(2):324-32.

Carpentier A.

1. *Ci X., Frisch F., Lavoie F., Germain P., Lecomte R., Van Lier J.E., Bénard F., **Carpentier A.C.** The effect of insulin on the intracellular Distribution of 14(R,S)-[18F]-fluoro-6-thiaheptadecanoic acid in rats. *Mol Imaging Biol.* 8(4):237-44, 2006.
2. **Carpentier AC**, Brassard P, Lavoie F, Frisch F, Bourbonnais A, Cyr D, Giguère R, **Baillargeon JP**. Mechanism of insulin-stimulated clearance of plasma non-esterified fatty acids in humans. *Am J Physiol Endocrinol Metab* 2007; 292(3): 693-701.
3. Brassard P, Frisch F, Lavoie F, Cyr D, Bourbonnais A, Cunnane SC, Patterson BW, Drouin R, **Baillargeon JP**, **Carpentier AC**. Impaired plasma non-esterified fatty acid tolerance is an early defect in the natural history of type 2 diabetes. *J Clin Endocrinol Metab.* 2008; 93(3): 837-844.
4. *Ménard SL, Ci X, Frisch F, Normand-Lauzière F, Cadorette J, Ouellet R, Van Lier JE, Bénard F, Bentourkia M, Lecomte R, **Carpentier AC**. Mechanism of reduced myocardial glucose utilization during acute hypertriglyceridemia in rats. *Mol Imaging Biol.* 2009 Jan-Feb;11(1):6-14
5. *Lavoie F, Frisch F, Brassard P, Normand-Lauzière F, Cyr D, Gagnon R, Drouin R, **Baillargeon JP**, **Carpentier AC**. Relationship between total and high molecular weight adiponectin levels and plasma nonesterified fatty acid tolerance during enhanced intravascular triacylglycerol lipolysis in men. *J Clin Endocrinol Metab.* 2009 Mar; 94(3):998-1004.

Chraibi A.

1. A.Goolaerts, J. Roux, V. Shlyonsky, S. Renauld, A. Matthay R.Naeije, S. Sohraby, M.Howard, **A. Chraibi**, and J-F Pittet. Serotonin Decreases Alveolar Epithelial Fluid Transport via a Direct Inhibition of the Epithelial Sodium Channel ENaC. *Am J Respir Cell Mol Biol.* 2009 Aug 28. [Epub ahead of print] PMID: 19717814 [PubMed - as supplied by publisher]
2. Renauld S, Allache R, **Chraibi A.** Ile481 from the guinea pig alpha-subunit plays a major role in the activation of ENaC by cpt-cAMP. *Cell Physiol Biochem.* 2008; 22(1-4):101-8.

3. S. Renaud and **A. Chraïbi**. Role of the C-Terminal Part of the Extracellular Domain of the α -ENaC in Activation by Sulfonyl-urea glibenclamide. *Journal of Membrane Biology*. 2009 Aug;230(3):133-41.
4. A.Goolaerts, J. Roux, V. Shlyonsky, S. Renaud, A. Matthay R.Naeije, S. Sohraby, M.Howard, **A. Chraïbi**, and J-F Pittet. Serotonin Decreases Alveolar Epithelial Fluid Transport via a Direct Inhibition of the Epithelial Sodium Channel ENaC. *Molecular Pharmacology Journal* 2007.
5. Wildman S., Marks J., Churchill L., Peppiatt C., **Chraïbi A.**, Shirley D., Horisberger JD, King B and R.Unwin. Regulatory interdependence of cloned epithelial Na⁺ channels and P2X receptors. *Journal of the American Society of Nephrology*. 2005; 16(9):2586-97.

Gallo-Payet N.

1. Beaudry H, Gendron L, Guimond MO, Payet MD et Gallo-Payet N. 2006 PKC alpha as a switch from proliferation to neurite outgrowth in NG108-15 cells (2005). *Endocrinology*, 147 (9):4263-4272
2. Otis M, Payet MD et Gallo-Payet N (2007) Role of MAPKs in angiotensin II-induced steroidogenesis in rat glomerulosa cells. *Mol. Cell. Endocrinology*, 265-266: 126-130.
3. Roy S et Gallo-Payet N Differential Regulation of the Human ACTH Receptor (MC2R) by human MC2R accessory protein (MRAP) isoforms α and β in isogenic HEK293 cells. (2007) *Mol. Endocrinology*, 21:1656-1659.
4. Murugaiah AM, Wallinder C, Mahalingam AK, Wan Y, Plouffe B, Botros M, Karlen, A, Hallberg M, **Gallo-Payet N** and Alterman M (2007). Selective angiotensin II AT(2) receptor agonists devoid of the imidazole ring system. *Bioorg Med Chem*. 5:7166-7183.
5. Otis M, Campbell S, Payet MD, Gallo-Payet N. In adrenal glomerulosa cells, Angiotensin II inhibits proliferation by interfering with fibronectin - integrin signaling. *Endocrinology*. 2008; 149(7):3435-45.

Hivert MF.

1. **Hivert MF, Langlois MF, Bérard P, Cuerrier JP, Carpentier AC**. Prevention of weight gain in young adults through a seminar-based intervention program. *Int J Obes (Lond)* 31(8):1262-9, 2007.
2. **Hivert MF, Manning AK, McAteer JB, Florez JC, Dupuis J, Fox CS, O'Donnell CJ, Cupples LA, Meigs JB**. Common variants in the adiponectin gene (*ADIPOQ*) associated with plasma adiponectin levels, type 2 diabetes, and diabetes-related quantitative traits: the Framingham Offspring Study. *Diabetes* 2008; 57(12):3353-9.
3. **Hivert MF, Sullivan LM, Fox CS, Nathan DM, Sr D'Agostino RB, Wilson PW, Meigs JB**. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. *J Clin Endocrinol Metab*. 2008 Aug; 93(8):3165-72.
4. **Hivert MF, Warner AS, Shrader P, Grant RW, Meigs JB**. Diabetes risk perception and intention to adopt healthy lifestyles among primary care patients. *Diabetes Care*. 2009
5. **Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB**. Circulating Interleukin-18 and the Risk of Type 2 Diabetes in Women. *Diabetologia*, 2009; 52(10):2101-8.

Langlois MF

1. **Poirier MB, Laflamme L, Langlois MF**. Identification and characterization of RanBPM, a novel coactivator of thyroid hormone receptors. *J Mol Endocrinol* 2006; 36: 313-325.

2. ***Baillargeon JP, Carpentier AC**, Donovan D, Fortin M, Grant A, Simoneau-Roy J, St-Cyr-Tribble D, Xhignesse M, **Langlois MF**. Integrated obesity care management system – Implementation and Research Protocol. *BMC Health Services Research* 2007; 7(1): 163-172.
3. **Poirier MB, Brunelle M, Langlois MF**. The effect of RanBPM on the regulation of the hypothalamic-pituitary axis by thyroid hormone receptors (TR) is isoform-specific. *Biochemical and Biophysical Research Communications* 2007; 362(2):516-21.
4. **Kamga-Ngandé CN, Carpentier AC**, Nadeau-Marcotte F, **Ardilouze JL, Baillargeon JP, Bellabarba D**, Houde G, **Langlois MF**. Effectiveness of a multidisciplinary program for management of obesity: the Unité d'Enseignement, de Traitement et de Recherche sur l'Obésité (UETRO) Database study. *Metabolic syndrome and related disorders* 2009;7(4):297-304.
5. ***Abdelouahab N, Suvorov A, Pasquier JC, Langlois MF**, Praud JP, Takser L. Thyroid Disruption by Low-Dose BDE-47 in Prenatally Exposed Lambs. *Neonatology*. 2009 Mar 24; 96(2):120-124.

Marsault E.

1. **Marsault, E.**; Hoveyda, H. R.; Peterson, M. L.; Gagnon, R.; Vezina, M.; Pinault, J. F.; Landry, A.; Saint-Louis, C.; Ouellet, L. G.; Beauchemin, S.; Benakli, K.; Beaubien, S.; Brassard, M.; Wang, Z.; Champagne, M.; Galaud, F.; Fortin, N.; Fortin, D.; Plourde, V.; Ramaseshan, M.; Bhat, S.; Bilodeau, F.; Lonergan, D.; Lan, R.; Li, S.; Berthiaume, G.; Foucher, L.; Peng, X.; Dory, Y.; Deslongchamps, P. High throughput solid phase parallel synthesis of macrocyclic peptidomimetics. *Adv Exp Med Biol* **2009**, 611, 15-6.
2. Beaubien, S.; Hoveyda, H. R.; Vezina, M.; **Marsault, E.**; Tremblay, H.; Foucher, L.; Benakli, K. Parallel solid-phase synthesis of macrocyclic peptidomimetics using Ru-catalyzed ring-closing metathesis and a new application of cross metathesis. *Adv Exp Med Biol* **2009**, 611, 13-4.
3. **Marsault, E.**; Hoveyda, H. R.; Gagnon, R.; Peterson, M. L.; Vezina, M.; Saint-Louis, C.; Landry, A.; Pinault, J. F.; Ouellet, L.; Beauchemin, S.; Beaubien, S.; Mathieu, A.; Benakli, K.; Wang, Z.; Brassard, M.; Lonergan, D.; Bilodeau, F.; Ramaseshan, M.; Fortin, N.; Lan, R.; Li, S.; Galaud, F.; Plourde, V.; Champagne, M.; Doucet, A.; Bherer, P.; Gauthier, M.; Olsen, G.; Villeneuve, G.; Bhat, S.; Foucher, L.; Fortin, D.; Peng, X.; Bernard, S.; Drouin, A.; Deziel, R.; Berthiaume, G.; Dory, Y. L.; Fraser, G. L.; Deslongchamps, P. Efficient parallel synthesis of macrocyclic peptidomimetics. *Bioorg Med Chem Lett* **2008**, 18, 4731-5.
4. **Marsault, E.**; Benakli, K.; Beaubien, S.; Saint-Louis, C.; Deziel, R.; Fraser, G. Potent macrocyclic antagonists to the motilin receptor presenting novel unnatural amino acids. *Bioorg Med Chem Lett* **2007**, 17, 4187-90.
5. **Marsault, E.**; Hoveyda, H. R.; Peterson, M. L.; Saint-Louis, C.; Landry, A.; Vezina, M.; Ouellet, L.; Wang, Z.; Ramaseshan, M.; Beaubien, S.; Benakli, K.; Beauchemin, S.; Deziel, R.; Peeters, T.; Fraser, G. L. Discovery of a new class of macrocyclic antagonists to the human motilin receptor. *J Med Chem* **2006**, 49, 7190-7.

Perron P.

1. **Perron P**, Brisson D, Santuré M, Blackburn P, Bergeron J, Vohl MC, Després JP, Gaudet D. Apolipoprotein E and Lipoprotein Lipase Gene Polymorphisms Interaction on the Atherogenic Combined Expression of Hypertriglyceridemia and Hyperapobetalipoproteinemia Phenotypes. *J Endocrinol Invest* 2007; 30(7) :551-7.

2. St-Pierre J, Lemieux I, **Perron P**, Brisson D, Santur  M, Vohl MC, Despr s JP, Gaudet D. Relation of the "Hypertriglyceridemic Waist" Phenotype to Earlier Manifestations of Coronary Artery Disease in Patients with Glucose Intolerance and Type 2 Diabetes Mellitus. *American Journal of Cardiology* 2007; 99(3) :369-73.
3. Bonnet J, McPherson R, Tedgui A, Simoneau D, Nozza A, Martineau P, Davignon J et **Perron P** (67 collaborateurs). Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: Results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. *Clinical Therapeutics*. 2008; 30 (12): 2298-2313.
4. Blackburn P, Lemieux I, Lamarche B, Bergeron J, **Perron P**, Tremblay G, Gaudet D, Despr s JP. Brief Report - Type 2 diabetes without the atherogenic metabolic triad does not predict angiographically-assessed coronary artery disease in women. *Diabetes Care*. 2008; 31(1):170-2.
5. Bouhali T, Brisson D, St-Pierre J, Tremblay G, **Perron P**, Laprise C, Vohl MC, Vissers MN, Hutten BA, Despr s JP, Kastelein JJ, Gaudet D. Low plasma adiponectin exacerbates the risk of premature coronary artery disease in familial hypercholesterolemia. *Atherosclerosis*. 2008; 196(1):262-9.